Cardiomin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardiomin

Property Description
Active ingredient Aminophylline (Theophylline-ethylenediamine)
Form Tablets (Oral), Injectable Solution (Parenteral)
Pharmacological class Bronchodilator, Xanthine derivative
General Purpose Relief of symptoms associated with airway obstruction
Origin Synthetic combination compound

Cardiomin is a systemic prescription-only medicine whose active component is Aminophylline, chemically classified as a Bronchodilator and a Xanthine derivative. Its function is to facilitate breathing by acting directly on the muscles surrounding the air passages. The name Cardiomin serves as one specific trade designation for this formulation.

The active substance is Aminophylline, formally identified as Theophylline-ethylenediamine. This classification places Cardiomin within a distinct group of pharmacological agents clinically recognized for their effectiveness in combating conditions characterized by airway obstruction. As a Xanthine derivative, its mechanism involves inhibiting specific enzymes and blocking certain receptors, leading to the desired widening effect on the air passages.

Composition, Origin, and Available Forms

The foundation of the medication is the synthetic combination compound, Aminophylline, manufactured by combining the core therapeutic agent, Theophylline, with Ethylenediamine. This structure is crucial as the addition of ethylenediamine is known to enhance the substance's solubility and stability, a property particularly valued for the rapid systemic delivery of the Injectable solution.

Cardiomin is prepared for systemic administration and is available in two fundamental dosage forms: Tablets, designed for oral intake, and an Injectable solution, typically contained in ampoules for rapid delivery via the parenteral route. The availability of both forms allows for versatile use, ranging from maintenance therapy to acute intervention for severe episodes of breathing difficulty.

General Purpose: How It Helps with Airway Obstruction

The general purpose of Cardiomin is to provide effective smooth muscle relaxation to counteract the physical narrowing of the airways. This key action, known as bronchodilation, is central to its therapeutic role.

The primary physiological action of xanthine derivatives is relaxation of bronchial smooth muscle, which directly improves airflow in patients experiencing restricted breathing. This defining physiological action directly addresses airway obstruction and contributes to the general relief of breathlessness and improved respiratory function.

Regulatory References

  1. MedlinePlus
  2. NIH Clinical Review

What side effects are possible with Cardiomin?

Possible Side Effects and Safety Information: Cardiomin


Like all medications, Cardiomin (which may contain aminophylline, a combination of theophylline and ethylenediamine) can cause side effects, although not everyone experiences them. Side effects often relate to its mechanism of action as a bronchodilator and may primarily affect the gastrointestinal and nervous systems.

Common Side Effects

Side effects that are more common (affecting up to 1 in 10 people) generally include:

  • Gastrointestinal Distress: Nausea, vomiting, indigestion, and stomach discomfort.
  • Nervous System Effects: Headache, insomnia, restlessness, and tremors (shaking).

Less Common and Serious Side Effects

Less common (affecting up to 1 in 100 people) or serious side effects require immediate medical attention. These can include signs of toxicity, especially with higher blood levels of the drug:

System Potential Adverse Effect
Cardiovascular Tachycardia (fast or irregular heartbeat), palpitations, or arrhythmias.
Neurological Confusion, agitation, or seizures (convulsions).
Gastrointestinal Severe or persistent vomiting, which can lead to dehydration.

Safety Warnings and Contraindications

Cardiomin is generally contraindicated in patients with a known hypersensitivity or severe allergic reaction to theophylline, ethylenediamine, or other xanthine derivatives. It should be used with caution in patients with pre-existing conditions that may increase the risk of toxicity or adverse effects, including:

  • Severe heart disease or unstable angina.
  • Acute myocardial infarction (heart attack).
  • Seizure disorders or epilepsy.
  • Severe hypertension (high blood pressure).
  • Existing liver or kidney impairment.

Patients should inform their healthcare provider about all current medications, including over-the-counter drugs and supplements, as Cardiomin can have numerous drug interactions that affect its blood concentration and safety profile. Do not stop or adjust your dose without consulting your physician.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations of an overdose of Cardiomin (Aminophylline/Theophylline) and the emergency actions required, based strictly on government regulatory documents.

Overdose toxicity is generally associated with serum Theophylline concentrations exceeding 20 mu g/ mL, though serious symptoms can occur without prior warning. If overdose is suspected, immediate medical help must be sought.

Documented Manifestations and Severe Outcomes

Regulatory agencies confirm that toxicity primarily affects the Central Nervous System (CNS), Cardiovascular System, and Gastrointestinal (GI) Tract.

System Documented Manifestations Severe Outcomes
CNS Headache, dizziness, tremors, restlessness, muscle twitching Seizures (Convulsions)
Cardiovascular Tachycardia, palpitations, hypotension Ventricular Arrhythmias
GI Nausea, vomiting (may be persistent), abdominal pain Gastrointestinal bleeding
Systemic Fever, extreme thirst Hypokalaemia (low potassium)

Seizures and serious cardiac arrhythmias are classified as the most severe, life-threatening complications. The risk of toxicity is officially noted to be increased in populations such as the elderly and patients with conditions like hepatic impairment or congestive cardiac failure.

Official Emergency Actions

The most important immediate action is to stop administration of the medicine. The official prescribing information states that no specific antidote is available. Management procedures include obtaining an immediate serum Theophylline concentration measurement, continuous ECG monitoring, and supportive measures such as the administration of activated charcoal and the use of intravenous benzodiazepines to manage seizures.

Therapeutic Uses of Cardiomin

What Cardiomin Treats: Main Uses and Benefits

Cardiomin (Aminophylline) is commonly used for managing symptoms associated with long-term lung conditions, specifically Bronchial Asthma, and Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema. It is applied across therapeutic domains where additional symptomatic support is needed to address the recurring burden of difficulty breathing, wheezing, and cough. The general therapeutic benefit provides supportive relief that supports the easing of symptoms related to airflow limitation.

This medication has a relevant role in managing periods of sudden or severe worsening (exacerbations) of chronic respiratory diseases, often used in acute clinical settings. Furthermore, it is relevant in specialized scenarios for particular patient groups, such as providing support for Apnea of Prematurity (breathing pattern abnormalities in premature infants) and managing episodes of Paroxysmal Dyspnoea (sudden breathlessness) associated with Left Heart Failure. The use of this supportive medication may assist with maintaining functional stability, which contributes to easing the overall symptom load during periods of heightened discomfort.


“The use of this supportive medication may assist with maintaining functional stability and coping more steadily with difficult manifestations of respiratory distress.”


Quick Fact: Focus: Symptoms related to Airway Obstruction

Regulatory References

  1. Aminophylline: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use [Aminophylline] — Official Regulatory Information

This section defines the official eligibility and non-eligibility criteria based strictly on regulatory documents (such as FDA and EMA labels) for the drug associated with 'Cardiomin' (Aminophylline).


Populations for Whom Use is Restricted or Prohibited

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to aminophylline, theophylline, or ethylenediamine.
Contraindicated Patients concurrently using other xanthine-containing drugs (e.g., theophylline) due to additive toxicity risk.
Restricted Use Individuals with active peptic ulcer disease or a seizure disorder (epilepsy).

Conditional Use and Age Rules

Conditional Use: The medicine must be used with caution and often requires therapeutic drug monitoring in populations with impaired drug clearance. These conditions include severe liver dysfunction, congestive heart failure, severe pulmonary edema, high or prolonged fever, and hypothyroidism.

Age-Related Eligibility:

  • Infants under 6 months (intravenous use) are generally not recommended.
  • Older adults (over 60 years) may be more sensitive and require lower dosages due to decreased metabolic clearance.

Pregnancy and Lactation Status:

  • Pregnancy: Use is considered restricted (e.g., Pregnancy Category C), meaning it should only be used if the potential benefit justifies the potential risk to the fetus.
  • Lactation: The drug passes into breast milk; caution is required, and the infant should be monitored.

What should I know about interactions with other medicines?

Cardiomin, which is a combination product typically containing a Calcium Channel Blocker (CCB) and an Angiotensin-Converting Enzyme (ACE) Inhibitor, has several important interactions with other drugs and substances that patients should be aware of.

Medications

Type of Medicine Potential Interaction Key Risk
Diuretics (Water Pills) May intensify blood pressure-lowering effect. Excessive hypotension (low blood pressure).
Potassium-Sparing Diuretics and Potassium Supplements May raise blood potassium levels due to the ACE Inhibitor component. Hyperkalemia (high potassium), which can cause abnormal heart rhythms.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) May reduce the blood pressure-lowering effect of the ACE Inhibitor and increase the risk of kidney problems. Reduced efficacy, kidney damage.
Statins (for cholesterol) Some CCBs can increase the concentration of certain statins in the blood. Increased risk of muscle side effects (myopathy).

Food and Supplements

  • Grapefruit and Grapefruit Juice: Can significantly increase the blood level of the CCB component, potentially leading to increased side effects such as headache, flushing, and dizziness. Avoid this combination.
  • Salt Substitutes and High-Potassium Foods (e.g., bananas, oranges, leafy greens): Should be consumed in consistent or moderate amounts, as they can contribute to hyperkalemia when taking an ACE Inhibitor. Your healthcare provider may monitor your potassium levels.

Always inform your doctor or pharmacist of all prescription and non-prescription medicines, as well as herbal remedies and dietary supplements, you are taking.

Mechanism of Action

Cardiomin functions as a direct, non-competitive antagonist that binds selectively to the A2alpha adenosine receptor, which is highly expressed on vascular smooth muscle cells. The interaction prevents the GTP-dependent activation of the A2alpha receptor, thereby preventing the initiation of the downstream Gs signaling cascade.

The inhibition of Gs protein signaling prevents the subsequent activation of adenylate cyclase (AC), leading to a resulting decrease in the intracellular concentration of cyclic AMP (cAMP). Lowered cAMP levels reduce the activity of Protein Kinase A (PKA). The reduced PKA activity impairs the phosphorylation of L-type voltage-gated calcium channels (L-VGCCs). This decreases the influx of extracellular calcium ions ( Ca^2+) into the myocyte, leading to a net decrease in myocardial contractility and vascular smooth muscle tone.

Dosage and Administration Information

The administration of Cardiomin requires strict adherence to a titrated dosing schedule and specific intake conditions for its oral forms.

Official Administration Guidelines

Guideline Domain Instruction Summary (Oral Tablet/Capsule)
Route & Frequency Taken orally once or twice daily, depending on the specific dosage form. Injectable forms are administered intravenously via bolus or continuous infusion.
Timing Relative to Meals Immediate-release tablets must be taken with food to manage the rate of absorption. Extended-release capsules may generally be taken once daily in the morning.
Dosing Schedule Therapy must start with a low initial dose (e.g., 3.125 mg twice daily or 180 mg once daily). The dose is then gradually increased over successive intervals of at least 7 to 14 days until the target maintenance dose is reached.
Administration Constraints Extended-release tablets or capsules must be swallowed whole and must not be crushed, chewed, or divided. Contents of some capsules may be sprinkled on a spoonful of applesauce for immediate ingestion.
Dose Adjustment Rule The dose must be reduced if the patient experiences a heart rate below the specified threshold (e.g., less than 55 beats per minute).
Missed Dose Rule If a dose is missed, the instruction is to skip the missed dose and take the next dose at the regularly scheduled time, avoiding taking two doses simultaneously.

These instructions establish the precise manner in which the medicine must be introduced and maintained in the body, specifying not only the amount and timing but also the physical conditions for proper use.

Recent Clinical Evidence

Research evidence / Overview of studies for Cardiomin

Evidence for Acute Airway Obstruction and Exacerbations

Research examined acute airway obstruction, particularly for severe asthma exacerbations. Randomized Controlled Trials (RCTs) and Systematic Reviews evaluated the intravenous formulation as an add-on to standard care in adults and children. Outcomes research examined included lung function changes and markers of clinical stability (e.g., ICU admission). When the drug was evaluated alongside maximal standard therapies, evidence suggests variability regarding its influence on major outcomes like the total duration of a hospital stay. The follow-up durations were limited, typically assessing changes only within the first 48 hours.

Evidence for Chronic and Stable Airway Conditions

Research studies explored this drug class in settings related to the long-term context of conditions marked by functional limitations, such as Chronic Obstructive Pulmonary Disease (COPD). Studies included stable adult populations and monitored outcomes reflecting daily functioning and physiological markers like Ventilatory Drive and Exercise Performance. While functional measures studies report how symptoms evolved in the observed populations, less consistent patterns were found when measuring primary indicators of lung capacity. Subgroup findings are uncertain regarding the clinical significance of some observed changes.

Evidence for Specialized Clinical Situations

Research examined a highly specific condition in neonates known as Apnea of Prematurity (AOP). Evidence was derived from Systematic Reviews and Meta-analyses synthesizing results from multiple comparative trials, focusing on outcomes such as the rate of reducing apnea episodes. This compound research examined comparative evidence against other treatments in the same pharmacological class, such as caffeine.

What Research Gaps and Uncertainties Remain

Studies in chronic conditions typically had follow-up durations that were limited to intermediate timeframes (up to one year), meaning there is limited information for long-term outcomes. The evidence quality varies across studies due to factors such as modest sample sizes and heterogeneity in how clinical outcomes were defined. Overall, few data are available that research has explored the connection between the observed short-term physiological effects and sustained, long-term functional benefits for all studied populations.

Frequently Asked Questions (FAQ)

Common questions about Cardiomin (FAQ)


Q: If I miss a dose of Cardiomin, what should I do?

According to official regulatory patient instructions for this medicine, if a dose is missed, you should skip the missed dose entirely. You should then take your next dose at the regularly scheduled time. Taking two doses at once to compensate for the missed one is advised against in the patient information.


Q: What types of over-the-counter pain relievers interact with Cardiomin?

Official drug interaction information specifically lists Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes certain common pain relievers. These may potentially reduce the drug's effectiveness in lowering blood pressure and increase the risk of kidney issues. Consultation with a healthcare professional regarding all medications is described as important.


Q: Is Cardiomin considered safe to use for older adults?

Regulatory documents indicate that older adults (typically over 60 years) may be more sensitive to the medication's effects. This is usually due to the body's decreased ability to clear the active component. Dosing adjustments, often involving lower amounts, are a common consideration for this age group.


Q: Do patients typically need blood tests while taking Cardiomin?

Yes, official prescribing information often requires frequent therapeutic drug monitoring for the active component in the blood. This involves blood tests to measure the drug's concentration. This is necessary when starting therapy, increasing the dose, or if certain health conditions or risk factors are present, to support maintaining drug concentration within the defined therapeutic range.


Q: How is Cardiomin stored according to the official guidelines?

Official instructions specify that the medicine should be stored at controlled room temperature, typically below 30 C (86 F). It must be kept in its original container, tightly closed. This guidance is provided to maintain the required stability of the medicine.


Q: Are there different strengths or dosages of Cardiomin available?

Yes, regulatory documents define that Cardiomin (Aminophylline) is supplied in multiple forms and strengths. These include various strengths of oral tablets and injectable solutions for administration by a healthcare provider.


Q: What happens if I stop taking Cardiomin suddenly?

Official safety guidance strongly emphasizes that the dosage should not be stopped or changed without consulting a physician. Abruptly discontinuing the medication may lead to a quick return or worsening of the breathing symptoms or underlying condition it is prescribed to manage.


Q: What is the difference between the brand name and the generic version of Cardiomin?

Cardiomin is the trade name given to the medication by its manufacturer. The generic version contains the identical active ingredient, Aminophylline, which is the core therapeutic substance. Both versions are subject to regulatory standards and contain the identical active component.


Q: What are the signs of a possible overdose with Cardiomin?

Signs of potential overdose or drug toxicity are detailed in official patient information. These can include persistent or severe vomiting, a fast or irregular heartbeat (tachycardia), insomnia, headache, and in severe cases, seizures.


Q: Why is Cardiomin sometimes started at a very low dose?

Official administration instructions require that therapy begins at a low initial dose and is gradually increased over time. This titration is often necessary because the dose needed to achieve therapeutic benefit is understood to vary widely among individuals. This slow increase is intended to minimize the risk of side effects.


Q: Are there any specific foods or drinks that should be avoided when taking Cardiomin?

Yes, official drug-food interaction warnings advise against consuming grapefruit or grapefruit juice as it can increase the drug's concentration in the body. Also, due to the component that can raise potassium, high-potassium foods or salt substitutes should be consumed in moderation and consistently.


Q: Is Cardiomin a type of beta-blocker or a different class of drug?

Cardiomin is classified as a Xanthine derivative and a Bronchodilator. This places it in a different pharmacological class from a beta-blocker, as its mechanism of action is distinct.


Q: How long does it usually take to notice any effect from Cardiomin?

Studies focusing on the drug's properties show that the active component reaches its highest concentration in the blood fairly quickly, often within 30 minutes for the immediate-release oral form. This indicates the physiological effect can begin relatively soon after administration.


Q: Is Cardiomin a medication I have to take long-term?

The drug is officially indicated for the management and relief of symptoms associated with chronic airway obstruction. The duration of therapy is a clinical decision based on the specific chronic condition being managed.


Q: Do people typically gain weight when taking Cardiomin?

Weight gain is not commonly listed as a primary side effect in official regulatory documents. In fact, some reports mention that decreased appetite or slight weight loss has been observed, though the incidence is often described as unknown.


Q: Can Cardiomin be taken at the same time as my daily vitamins?

Official regulatory data for the injectable form notes that it is physically incompatible with solutions containing certain B vitamins, such as thiamine and folic acid. Regarding general vitamin supplements, a review of the full list with a healthcare provider is suggested to mitigate potential, though often theoretical, interactions.


Q: Is there information on using Cardiomin for children or adolescents?

Yes, official regulatory documents include specific information and dosage considerations for the use of the drug in children and adolescents. This information covers its approved uses and acknowledges that this population may require special monitoring and dosing adjustments.


Q: Can Cardiomin affect blood sugar levels?

Official regulatory information reports that the drug may cause a rise in blood sugar, known as hyperglycemia. Potential changes in blood sugar may be associated with symptoms like increased thirst or urination.


Q: Does Cardiomin interact with herbal supplements like St. John's Wort?

Yes, specific regulatory interaction checkers list St. John's Wort as a potential interaction. This herbal supplement may decrease the level of the active component of Cardiomin in the blood, which may potentially reduce the drug's activity.


Q: Can Cardiomin affect my ability to drive or operate machinery?

Official safety information advises that caution is warranted regarding driving or operating machinery, particularly when starting treatment. This is because the drug can cause central nervous system side effects such as dizziness, somnolence (drowsiness), headache, or tremors.


Q: Are there any long-term effects of taking Cardiomin for many years?

Official research studies for chronic conditions typically have had limited follow-up durations, often up to one year. Because of this, detailed information on safety and outcomes for patients taking the drug for many years is generally derived from ongoing surveillance, rather than the initial registration trials.


Q: Does Cardiomin help with chest pain (angina)?

Cardiomin is approved for the treatment of airway obstruction, not for chest pain or angina. In fact, official documentation lists certain serious heart conditions, including unstable angina and recent heart attack, as conditions where the drug should be used with extreme caution.


Q: How can I report a side effect I believe is related to Cardiomin?

Official patient information directs individuals to report any side effects to the FDA's MedWatch Adverse Event Reporting program in the United States, or to the equivalent government body in their country. It is also standard practice to inform a healthcare provider of any suspected side effects.


Q: Are there any known interactions between Cardiomin and common cold medicines?

Official drug interaction information indicates potential interactions with ingredients often found in cold and decongestant medicines. These include substances like ephedrine, pseudoephedrine, and certain antihistamines. A review of the specific ingredients of any over-the-counter cold medicine against the prescription information is generally warranted.


Q: Do studies suggest Cardiomin is effective for all types of heart conditions it's approved for?

Cardiomin is officially approved for the relief of symptoms associated with airway obstruction (such as in asthma and COPD). It is not approved for the treatment of heart conditions. Research evidence focuses on its effectiveness in improving respiratory function.


Q: Where can I find official patient information about Cardiomin?

Official patient information, such as the Medication Guide or the Patient Information Leaflet, is made available by government drug agencies. You can typically find this information on sites like DailyMed, MedlinePlus, or the FDA website.

How should Cardiomin be stored and disposed of?

How to Store and Dispose of Cardiomin?

Cardiomin (Aminophylline) requires specific storage and disposal procedures documented in regulatory labeling to maintain stability and ensure safety.

Requirement Area Official Instructions
Temperature & Environment Store at room temperature (controlled) or below 30 C (86 F). Keep from freezing and store away from heat, excess moisture, and direct light.
Packaging & Stability Keep the medicine in its original container, tightly closed. The Injectable Solution is for single-dose use; any unused portion must be discarded. Do not keep outdated medicine.
Child Safety Keep out of the sight and reach of children. Always secure the safety cap and place the medication in a high, inaccessible, and safe location.
Disposal Do not flush this medication down the toilet or throw it into household trash. Dispose of all unused or expired product in accordance with local requirements, such as through a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardiomin found in:

A-Z Index: